Silencing aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway

The therapeutic effects of standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy for prevalent lymphoma diffuse large B-cell lymphoma (DLBC, DLBCL) still require improvement. Cancer related aurora-kinase-A (AURKA) may work as a target for DLBCL treatment and its effect on...

Full description

Bibliographic Details
Main Authors: Shaoxiong Wang, Li Sun
Format: Article
Published: Taylor & Francis Group 2021-09-01
Online Access: